The landscape of pharmacological interventions for type 2 diabetes and obesity is rapidly evolving, with GLP-3 receptor activators taking center stage. Initially, drugs like Reta, demonstrating impressive glucose https://orlandoxzlm287844.idblogmaker.com/37822021/glp-3-receptor-agonists-reta-trizepatide-and-beyond